ISCHEMIA Trial Explained
09 min
July 7, 2026
Overview
This module reviews the role of SGLT2 inhibitors in heart failure across the spectrum of EF. We discuss mechanisms, landmark trials, patient selection, expected benefits, safety considerations, and practical prescribing tips.
Clinical Bottom Line
- SGLT2 inhibitors reduce HF hospitalization and CV mortality across EF spectrum.
- Benefits observed in HFrEF, HFmrEF and HFpEF.
- Use irrespective of diabetes status.
- Monitor renal function and volume status.
- Class I recommendation in major guidelines for appropriate patients.
What You’ll Learn
- How SGLT2 inhibitors work beyond glucose lowering
- Evidence from major RCTs and meta-analyses
- Which patients benefit the most
- Dosing, safety and monitoring
- Practical clinical tips
Key Topics Covered
- Mechanism of action
- DAPA-HF & EMPEROR-Reduced
- EMPEROR-Preserved
- Patient selection
- Safety & monitoring
- Clinical application
Clinical Pearls
- Start early, don’t wait for advanced HF.
- Minimal BP lowering; ideal for multi-drug regimens.
- Watch for genital infections and volume depletion.
- Sick day rules and patient education are key.
References
Key references and guidelines used in this module.
About this Module
Start your journey to a healthier heart with trusted videos, expert tips and practical guidance.
Category
Drug Review
Sub category
Drugs
